Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592272 | SCV000702008 | uncertain significance | not provided | 2016-10-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001302577 | SCV001491791 | likely benign | FGFR2-related craniosynostosis | 2024-09-15 | criteria provided, single submitter | clinical testing | |
Daryl Scott Lab, |
RCV002245031 | SCV002515327 | uncertain significance | FGFR2-realated disorder | 2022-02-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483578 | SCV002785445 | uncertain significance | Acrocephalosyndactyly type I; Beare-Stevenson cutis gyrata syndrome; Jackson-Weiss syndrome; Levy-Hollister syndrome; Pfeiffer syndrome; Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis; Crouzon syndrome; Saethre-Chotzen syndrome; Familial scaphocephaly syndrome, McGillivray type; Bent bone dysplasia syndrome 1; Gastric cancer | 2021-10-25 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004737855 | SCV005344725 | uncertain significance | FGFR2-related disorder | 2024-06-06 | no assertion criteria provided | clinical testing | The FGFR2 c.289G>A variant is predicted to result in the amino acid substitution p.Ala97Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.032% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |